Evvy has launched the Evvy UTI+ Test, an at-home urine test that uses PCR technology to detect 12 key uropathogens and 7 antibiotic resistance markers. Results are delivered in one business day. Eligible patients can receive same-day, targeted prescription care based on their results.
Standard urine cultures can miss up to 60-70% of pathogens, and results often take days to return. Nearly one in two women receive an antibiotic that may not effectively address their infection, leading to prolonged symptoms, repeat appointments, and unnecessary antibiotic exposure.
“At Evvy, we believe women deserve better than guesswork,” said Dr. Kate McLean, OBGYN and Chief Medical Officer at Evvy. “We designed the UTI+ Test to solve a big failure of current UTI care: incomplete detection. By using PCR to identify 12 key pathogens, we can treat UTIs with accuracy and precision. The result is simple but profound – patients finally get better without the trial-and-error approach that has plagued UTI care for generations.”
UTIs are the most common infection in US women. One in four women experience recurring UTIs.
Evvy is known for its vaginal microbiome test kits. Research shows that the vaginal microbiome can play a role in urinary health by acting as a reservoir for UTI-causing bacteria. In Evvy’s dataset, 47% of users who reported a recent UTI had UTI-related bacteria detected in their vaginal microbiome.
The UTI+ Test is available in the US except Alaska, Hawaii, and New York at $248, or $218 with a subscription.
